{"id":1250,"date":"2022-05-22T16:43:00","date_gmt":"2022-05-22T14:43:00","guid":{"rendered":"http:\/\/mtl.hamstage.hamrenmedia.se\/interview-with-elisabet-schesny-of-the-swedish-breast-cancer-association\/"},"modified":"2023-03-28T10:51:51","modified_gmt":"2023-03-28T08:51:51","slug":"intervju-med-brostcancerforbundets-elisabet-schesny","status":"publish","type":"post","link":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/","title":{"rendered":"Intervju med Br\u00f6stcancerf\u00f6rbundets Elisabet Schesny"},"content":{"rendered":"\n
Elisabet Schesny \u00e4r vice ordf\u00f6rande f\u00f6r Br\u00f6stcancerf\u00f6rbundet, Sveriges enda intresseorganisation som fokuserar enbart p\u00e5 br\u00f6stcancer. F\u00f6rbundet, med 11 000 medlemmar, deltar i MedTechLabs patientr\u00e5d.<\/pre>\n\n\n\n
Hej Elisabeth, vad kommer ni att arbeta med under val\u00e5ret?<\/strong><\/p>\n\n\n\n
\u2013 Vi fokuserar p\u00e5 kravet om j\u00e4mlik v\u00e5rd som \u00e4r otroligt viktigt f\u00f6r v\u00e5rt f\u00f6rbund. Det inneb\u00e4r att vi lyfter fr\u00e5gor om inf\u00f6rande av metoder f\u00f6r individualiserad screening baserad p\u00e5 kvinnans risk att utveckla br\u00f6stcancer (idag f\u00e5r alla samma screening genom mammografiprogrammet), alla patienters r\u00e4tt till rehabilitering och tillg\u00e5ng till nya l\u00e4kemedel j\u00e4mlikt \u00f6ver Sverige<\/p>\n\n\n\n
Vilka utmaningar ser du runt nya behandlingar i v\u00e5rden?<\/strong><\/p>\n\n\n\n
\u2013 Det \u00e4r s\u00e5klart frustrerande att det tar l\u00e5ng tid att f\u00e5 in nya l\u00e4kemedel och ny teknik i v\u00e5rden. Att l\u00e4kemedel som f\u00f6rst godk\u00e4nts av amerikanska FDA sen ska g\u00e5 igenom samma sak med den europeiska l\u00e4kemedelsmyndigheten EMA f\u00f6r att slutligen godk\u00e4nnas h\u00e4r i Sverige tar l\u00e5ng tid. Sen \u00e4r det ett problem att Sverige har s\u00e5 m\u00e5nga regioner med sina egna budgetar och att inf\u00f6randet av nya behandlingar och ny teknik d\u00e4rf\u00f6r inte sker j\u00e4mlikt. Det ska inte spela n\u00e5gon roll var i landet man bor. F\u00f6r patienten handlar det om liv eller d\u00f6d vid en allvarlig sjukdom s\u00e5som br\u00f6stcancer.<\/p>\n\n\n\n
Hur kan man \u00e4ndra p\u00e5 det?<\/strong><\/p>\n\n\n\n
\u2013 Vi driver sj\u00e4lva fr\u00e5gan om j\u00e4mlik v\u00e5rd, den \u00e4r j\u00e4tteviktigt f\u00f6r oss. Som det \u00e4r nu g\u00f6r regionerna olika prioriteringar och det kan d\u00e4rf\u00f6r ta olika l\u00e5ng tid f\u00f6r patienter att f\u00e5 tillg\u00e5ng till en ny behandling. En m\u00f6jlighet man kunde \u00f6verv\u00e4ga \u00e4r att centralisera implementeringsdelen, men inte den operativa v\u00e5rdinsatsen. Br\u00f6stcancerf\u00f6rbundet har gjort en kartl\u00e4ggning<\/a> som visade att bara fyra av tio med den vanligaste formen av spridd br\u00f6stcancer fick behandlingar i linje med aktuell forskning och rekommendationer. Vi anv\u00e4nder bland annat detta exempel i v\u00e5rt p\u00e5verkans-och opinionsarbete f\u00f6r att visa att det inte r\u00e5der j\u00e4mlik v\u00e5rd p\u00e5 br\u00f6stcanceromr\u00e5det.<\/p>\n\n\n\n
Hur kan man f\u00e5 fler att vilja delta i kliniska studier?<\/strong><\/p>\n\n\n\n
\u2013 Med nuvarande situation d\u00e4r en studie ofta \u00e4r f\u00f6rlagd till ett st\u00f6rre regionalt sjukhus kan det kan bli sv\u00e5rt att rekrytera brett. Man kan fundera \u00f6ver om kliniska studier borde vara nationella och inkludera flera sjukhus utspridda \u00f6ver landet. Forskningssjuksk\u00f6terskorna finns p\u00e5 de stora sjukhusen, men hur kan vi f\u00e5 fler till de mindre sjukhusen? Den multidisciplin\u00e4ra konferensen som diskuterar patientfallen har en roll att bed\u00f6ma l\u00e4mpliga kliniska studier f\u00f6r varje patient. Behandlande l\u00e4kare \u00e4r de som ska informera patienterna. \u00c4ven kontaktsjuksk\u00f6terskorna borde kunna informera sina patienter. B\u00e5da dessa yrkesgrupper beh\u00f6ver vara v\u00e4l informerade om vilka kliniska studier som kan vara relevanta f\u00f6r deras patienter och vilka f\u00f6rdelar som finns f\u00f6r patienten att delta i studien. Ofta finns ocks\u00e5 skriftlig information i v\u00e4ntrummet om kliniska studier som man vill rekrytera patienter till, men patienter i v\u00e4ntrum fokuserar p\u00e5 helt andra saker innan sitt l\u00e4karbes\u00f6k d\u00e5 man kan vara r\u00e4dd och orolig inf\u00f6r ett besked som l\u00e4karen ska l\u00e4mna. Sen kan informationen om den enskilda kliniska studien vara komplicerad, n\u00e4r den tv\u00e4rtom beh\u00f6ver vara patientv\u00e4nlig och l\u00e4ttf\u00f6rst\u00e5elig. I designfasen av en klinisk studie finns en massa saker som patientf\u00f6retr\u00e4dare kan bidra med, till exempel insikter om f\u00f6rv\u00e4ntad oro och obehag f\u00f6r vissa delar av studien eller att inte orimliga krav st\u00e4lls till exempel vad g\u00e4ller antal bes\u00f6k p\u00e5 sjukhuset f\u00f6r patienten att fullf\u00f6lja olika delar i studien. Ofta \u00e4r medverkan fr\u00e5n patientf\u00f6retr\u00e4dare begr\u00e4nsad till vissa avgr\u00e4nsade delar, men i vissa fall \u00e4r det fr\u00e5gan om ett st\u00f6rre engagemang d\u00e4r patientf\u00f6retr\u00e4daren n\u00e4stan blir en j\u00e4mb\u00f6rdig part. D\u00e5 \u00e4r det ocks\u00e5 rimligt att diskutera fr\u00e5gan om ers\u00e4ttning till patientf\u00f6retr\u00e4dare som deltar och n\u00e5got som forskningsprojektet borde budgetera f\u00f6r fr\u00e5n b\u00f6rjan.<\/p>\n\n\n\n
Hur ser du p\u00e5 er medverkan i MedTechLabs patientr\u00e5d?<\/strong><\/p>\n\n\n\n
\u2013 Det har blivit vanligare att man f\u00f6rs\u00f6ker f\u00e5 med patientf\u00f6retr\u00e4dare i forskningsprocessen, som vid MedTechLabs, och vi vill g\u00e4rna bidra utifr\u00e5n de resurser och m\u00f6jligheter vi har. Patienter \u00e4r i allm\u00e4nhet inte \u00e4r s\u00e5 v\u00e4l informerade om innovation runt medicinteknik och vad det kan inneb\u00e4ra f\u00f6r dem, hur forskningen implementeras och hur h\u00f6gteknologiska maskiner fungerar. Det kan ocks\u00e5 vara sv\u00e5rt att f\u00f6rst\u00e5 vad ett tv\u00e4rvetenskapligt centrum g\u00f6r och vad det inneb\u00e4r att det \u00e4r partsammansatt, att industrin m\u00e5ste finnas med i sammanhanget. S\u00e5 genom att delta i patientr\u00e5det hoppas jag att kunna p\u00e5verka s\u00e5 att v\u00e5ra medlemmar och andra m\u00e5lgrupper kan l\u00e4ra sig mer om vad forskningen kan betyda f\u00f6r br\u00f6stcancerpatienter, till exempel genom att uppmuntra MedTechLabs att informera om sin verksamhet p\u00e5 ett l\u00e4ttf\u00f6rst\u00e5eligt s\u00e4tt.<\/p>\n\n\n\n
L\u00e4s mer om Br\u00f6stcancerf\u00f6rbundet p\u00e5 brostcancerforbundet.se\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
Hej Elisabeth, vad kommer ni att arbeta med under val\u00e5ret? \u2013 Vi fokuserar p\u00e5 kravet om j\u00e4mlik v\u00e5rd som \u00e4r otroligt viktigt f\u00f6r v\u00e5rt f\u00f6rbund. Det inneb\u00e4r att vi lyfter fr\u00e5gor om inf\u00f6rande av metoder f\u00f6r individualiserad screening baserad p\u00e5 kvinnans risk att utveckla br\u00f6stcancer (idag f\u00e5r alla samma screening genom mammografiprogrammet), alla patienters r\u00e4tt […]<\/p>\n","protected":false},"author":1,"featured_media":833,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[57],"tags":[],"class_list":["post-1250","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-interviews-sv"],"acf":[],"yoast_head":"\nIntervju med Br\u00f6stcancerf\u00f6rbundets Elisabet Schesny - Medtechlabs<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intervju med Br\u00f6stcancerf\u00f6rbundets Elisabet Schesny - Medtechlabs\" \/>\n<meta property=\"og:description\" content=\"Hej Elisabeth, vad kommer ni att arbeta med under val\u00e5ret? \u2013 Vi fokuserar p\u00e5 kravet om j\u00e4mlik v\u00e5rd som \u00e4r otroligt viktigt f\u00f6r v\u00e5rt f\u00f6rbund. Det inneb\u00e4r att vi lyfter fr\u00e5gor om inf\u00f6rande av metoder f\u00f6r individualiserad screening baserad p\u00e5 kvinnans risk att utveckla br\u00f6stcancer (idag f\u00e5r alla samma screening genom mammografiprogrammet), alla patienters r\u00e4tt […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/\" \/>\n<meta property=\"og:site_name\" content=\"Medtechlabs\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-22T14:43:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-28T08:51:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/03\/Portrattbild-Elisabet-Schesny-Brostcancerforbundet.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"hamren\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Skriven av\" \/>\n\t<meta name=\"twitter:data1\" content=\"hamren\" \/>\n\t<meta name=\"twitter:label2\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/\"},\"author\":{\"name\":\"hamren\",\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#\/schema\/person\/434303f2fc5cc654e7aae9b6dd7a0610\"},\"headline\":\"Intervju med Br\u00f6stcancerf\u00f6rbundets Elisabet Schesny\",\"datePublished\":\"2022-05-22T14:43:00+00:00\",\"dateModified\":\"2023-03-28T08:51:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/\"},\"wordCount\":883,\"publisher\":{\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#organization\"},\"image\":{\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/03\/Portrattbild-Elisabet-Schesny-Brostcancerforbundet.jpeg\",\"articleSection\":[\"Intervjuer\"],\"inLanguage\":\"sv-SE\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/\",\"url\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/\",\"name\":\"Intervju med Br\u00f6stcancerf\u00f6rbundets Elisabet Schesny - Medtechlabs\",\"isPartOf\":{\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/03\/Portrattbild-Elisabet-Schesny-Brostcancerforbundet.jpeg\",\"datePublished\":\"2022-05-22T14:43:00+00:00\",\"dateModified\":\"2023-03-28T08:51:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#primaryimage\",\"url\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/03\/Portrattbild-Elisabet-Schesny-Brostcancerforbundet.jpeg\",\"contentUrl\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/03\/Portrattbild-Elisabet-Schesny-Brostcancerforbundet.jpeg\",\"width\":1280,\"height\":1280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intervju med Br\u00f6stcancerf\u00f6rbundets Elisabet Schesny\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#website\",\"url\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/\",\"name\":\"Medtechlabs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#organization\",\"name\":\"Medtechlabs\",\"url\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/02\/medtechlabs_logo_RGB_orange-65.png\",\"contentUrl\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/02\/medtechlabs_logo_RGB_orange-65.png\",\"width\":480,\"height\":60,\"caption\":\"Medtechlabs\"},\"image\":{\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#\/schema\/person\/434303f2fc5cc654e7aae9b6dd7a0610\",\"name\":\"hamren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7057011de81052044391537cdb2a848061d23579e007d1cf6d51dfc39d69302e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7057011de81052044391537cdb2a848061d23579e007d1cf6d51dfc39d69302e?s=96&d=mm&r=g\",\"caption\":\"hamren\"},\"sameAs\":[\"https:\/\/mtl.hamstage2.hamrenmedia.se\"],\"url\":\"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/author\/hamren\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intervju med Br\u00f6stcancerf\u00f6rbundets Elisabet Schesny - Medtechlabs","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/","og_locale":"sv_SE","og_type":"article","og_title":"Intervju med Br\u00f6stcancerf\u00f6rbundets Elisabet Schesny - Medtechlabs","og_description":"Hej Elisabeth, vad kommer ni att arbeta med under val\u00e5ret? \u2013 Vi fokuserar p\u00e5 kravet om j\u00e4mlik v\u00e5rd som \u00e4r otroligt viktigt f\u00f6r v\u00e5rt f\u00f6rbund. Det inneb\u00e4r att vi lyfter fr\u00e5gor om inf\u00f6rande av metoder f\u00f6r individualiserad screening baserad p\u00e5 kvinnans risk att utveckla br\u00f6stcancer (idag f\u00e5r alla samma screening genom mammografiprogrammet), alla patienters r\u00e4tt […]","og_url":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/","og_site_name":"Medtechlabs","article_published_time":"2022-05-22T14:43:00+00:00","article_modified_time":"2023-03-28T08:51:51+00:00","og_image":[{"width":1280,"height":1280,"url":"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/03\/Portrattbild-Elisabet-Schesny-Brostcancerforbundet.jpeg","type":"image\/jpeg"}],"author":"hamren","twitter_card":"summary_large_image","twitter_misc":{"Skriven av":"hamren","Ber\u00e4knad l\u00e4stid":"4 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#article","isPartOf":{"@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/"},"author":{"name":"hamren","@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#\/schema\/person\/434303f2fc5cc654e7aae9b6dd7a0610"},"headline":"Intervju med Br\u00f6stcancerf\u00f6rbundets Elisabet Schesny","datePublished":"2022-05-22T14:43:00+00:00","dateModified":"2023-03-28T08:51:51+00:00","mainEntityOfPage":{"@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/"},"wordCount":883,"publisher":{"@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#organization"},"image":{"@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#primaryimage"},"thumbnailUrl":"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/03\/Portrattbild-Elisabet-Schesny-Brostcancerforbundet.jpeg","articleSection":["Intervjuer"],"inLanguage":"sv-SE"},{"@type":"WebPage","@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/","url":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/","name":"Intervju med Br\u00f6stcancerf\u00f6rbundets Elisabet Schesny - Medtechlabs","isPartOf":{"@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#primaryimage"},"image":{"@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#primaryimage"},"thumbnailUrl":"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/03\/Portrattbild-Elisabet-Schesny-Brostcancerforbundet.jpeg","datePublished":"2022-05-22T14:43:00+00:00","dateModified":"2023-03-28T08:51:51+00:00","breadcrumb":{"@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/"]}]},{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#primaryimage","url":"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/03\/Portrattbild-Elisabet-Schesny-Brostcancerforbundet.jpeg","contentUrl":"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/03\/Portrattbild-Elisabet-Schesny-Brostcancerforbundet.jpeg","width":1280,"height":1280},{"@type":"BreadcrumbList","@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/intervju-med-brostcancerforbundets-elisabet-schesny\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/"},{"@type":"ListItem","position":2,"name":"Intervju med Br\u00f6stcancerf\u00f6rbundets Elisabet Schesny"}]},{"@type":"WebSite","@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#website","url":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/","name":"Medtechlabs","description":"","publisher":{"@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#organization","name":"Medtechlabs","url":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#\/schema\/logo\/image\/","url":"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/02\/medtechlabs_logo_RGB_orange-65.png","contentUrl":"https:\/\/mtl.hamstage2.hamrenmedia.se\/wp-content\/uploads\/2023\/02\/medtechlabs_logo_RGB_orange-65.png","width":480,"height":60,"caption":"Medtechlabs"},"image":{"@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#\/schema\/person\/434303f2fc5cc654e7aae9b6dd7a0610","name":"hamren","image":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7057011de81052044391537cdb2a848061d23579e007d1cf6d51dfc39d69302e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7057011de81052044391537cdb2a848061d23579e007d1cf6d51dfc39d69302e?s=96&d=mm&r=g","caption":"hamren"},"sameAs":["https:\/\/mtl.hamstage2.hamrenmedia.se"],"url":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/author\/hamren\/"}]}},"_links":{"self":[{"href":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/wp-json\/wp\/v2\/posts\/1250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/wp-json\/wp\/v2\/comments?post=1250"}],"version-history":[{"count":1,"href":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/wp-json\/wp\/v2\/posts\/1250\/revisions"}],"predecessor-version":[{"id":1252,"href":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/wp-json\/wp\/v2\/posts\/1250\/revisions\/1252"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/wp-json\/wp\/v2\/media\/833"}],"wp:attachment":[{"href":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/wp-json\/wp\/v2\/media?parent=1250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/wp-json\/wp\/v2\/categories?post=1250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mtl.hamstage2.hamrenmedia.se\/sv\/wp-json\/wp\/v2\/tags?post=1250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}